Oct 03, 2018 - Clovis Oncology has struggled to set itself apart from other PARP inhibitor developers over the past few years.A new breakthrough therapy designation could signal a move into an alternate disease land
Oct 03, 2018 - Clovis' (CLVS) cancer drug, Rubraca, gets Breakthrough Therapy designation from the FDA for treating metastatic castration resistant prostate cancer with BRCA mutation.
Oct 03, 2018 - A diversified portfolio, robust pipeline, strong growth of new drugs and a consistent dividend payout make Johnson & Johnson (JNJ) a good bet amid market turmoil as well as over the long term.
Sep 07, 2018 - The company is advancing a research program that it hopes will improve outcomes for patients with non-small cell lung cancer.
Jul 12, 2018 - Constellation Pharmaceuticals intends to sell $80 million of its common stock in a U.S. IPO.The firm is developing treatment candidates for a variety of cancers and myelofibrosis diseases.CNST has sho
Jul 12, 2018 - Understanding the root cause for the falling stock price in the last 1.5 years.Improved upside for future revenue growth with more indications.Strong pipeline on Immunotherapy assets.Slightly underval
Jul 06, 2018 - Clovis Oncology's (CLVS) regulatory application seeking label expansion of Rubraca as maintenance treatment was accepted for review in Europe.
Jun 02, 2018 - Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday
Jun 01, 2018 - Tesaro traded into the deep south for the past 52 weeks. Nevertheless, the fundamentals are improving, thus signaling a trading reversal in the making.Revenues from the approved product, niraparib (Ze
May 30, 2018 - Clovis Oncology's (CLVS) PARP inhibitor, Rubraca, gets its first approval in Europe for the treatment of BRCA-mutant ovarian cancer in third- or later-line setting.